Lake Street Initiates Coverage On Silk Road Medical with Buy Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Lake Street analyst Frank Takkinen has initiated coverage on Silk Road Medical (NASDAQ:SILK) with a Buy rating and set a price target of $20.
January 03, 2024 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silk Road Medical has been given a Buy rating and a price target of $20 by Lake Street analyst Frank Takkinen.
The initiation of coverage by an analyst with a Buy rating typically suggests a positive outlook on the stock's future performance. The price target of $20 indicates a potential upside from the current trading price, which may attract investor interest and drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100